Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa J Christopher

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Scientific Reports|December 23, 2022
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitorVidya Perera, Zhaoqing Wang, Susan Lubin, et al.
Cardiology and Therapy|May 31, 2022
Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa InhibitorVidya Perera, Zhaoqing Wang, Susan Lubin, et al.
British Journal of Clinical Pharmacology|July 25, 2012
Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozinDavid W Boulton, Sreeneeranj Kasichayanula, Chi Fung Anther Keung, et al.
Journal of Clinical Pharmacology|February 26, 2013
Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulationsZheng Yang, Blisse Vakkalagadda, Guoxiang Shen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 13, 2012
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in humanHong Su, David W Boulton, Anthony Barros, et al.
Clinical and Translational Science|October 25, 2024
Absolute oral bioavailability of milvexian spray-dried dispersion formulation under fasted and fed conditions in healthy adult participants: An intravenous microtracer approachPraneeth Jarugula, Sharif Soleman, Hyunmoon Back, et al.
Chemical Research in Toxicology|November 18, 2010
Mechanistic studies on a P450-mediated rearrangement of BMS-690514: conversion of a pyrrolotriazine to a hydroxypyridotriazineHaizheng Hong, Janet Caceres-Cortes, Hong Su, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|June 21, 2021
Preclinical metabolism and disposition of an orally bioavailable macrocyclic FXIa inhibitorSilvi A Chacko, Wu Yang, Yufeng Wang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 6, 2010
Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogsHaizheng Hong, Hong Su, Haojun Sun, et al.
Bioanalysis|November 19, 2016
UHPLC-MS/MS bioanalysis of urinary DHEA, cortisone and their hydroxylated metabolites as potential biomarkers for CYP3A-mediated drug-drug interactionsNaiyu Zheng, Lisa J Christopher, Xuewen Ma, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Scientific Reports|December 23, 2022
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitorVidya Perera, Zhaoqing Wang, Susan Lubin, et al.
Cardiology and Therapy|May 31, 2022
Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa InhibitorVidya Perera, Zhaoqing Wang, Susan Lubin, et al.
British Journal of Clinical Pharmacology|July 25, 2012
Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozinDavid W Boulton, Sreeneeranj Kasichayanula, Chi Fung Anther Keung, et al.
Journal of Clinical Pharmacology|February 26, 2013
Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulationsZheng Yang, Blisse Vakkalagadda, Guoxiang Shen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 13, 2012
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in humanHong Su, David W Boulton, Anthony Barros, et al.
Clinical and Translational Science|October 25, 2024
Absolute oral bioavailability of milvexian spray-dried dispersion formulation under fasted and fed conditions in healthy adult participants: An intravenous microtracer approachPraneeth Jarugula, Sharif Soleman, Hyunmoon Back, et al.
Chemical Research in Toxicology|November 18, 2010
Mechanistic studies on a P450-mediated rearrangement of BMS-690514: conversion of a pyrrolotriazine to a hydroxypyridotriazineHaizheng Hong, Janet Caceres-Cortes, Hong Su, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|June 21, 2021
Preclinical metabolism and disposition of an orally bioavailable macrocyclic FXIa inhibitorSilvi A Chacko, Wu Yang, Yufeng Wang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 6, 2010
Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogsHaizheng Hong, Hong Su, Haojun Sun, et al.
Bioanalysis|November 19, 2016
UHPLC-MS/MS bioanalysis of urinary DHEA, cortisone and their hydroxylated metabolites as potential biomarkers for CYP3A-mediated drug-drug interactionsNaiyu Zheng, Lisa J Christopher, Xuewen Ma, et al.
Pageof 4